W.A. Rasic Construction Awarded Major Subcontract on Dragados' $630M Effluent Outfall Tunnel Project in Los Angeles County
The $630 million project, commissioned by the Los Angeles County Sanitation Districts (Sanitation Districts), aims to significantly upgrade the region's wastewater discharge capabilities. With a planned completion in October 2026, the tunnel will span from the JWPCP Shaft Site in Carson to Royal Palms Beach in Rancho Palos Verdes, traveling as deep as 450 feet below ground.
As part of its subcontract, W.A. Rasic Construction will lead the installation of massive 144-inch (12-foot) diameter pipeline segments—critical to conveying treated effluent through the new tunnel. The pipe system will connect the existing JWPCP force main to the new tunnel shaft, facilitating long-term improvements in capacity, environmental protection, and seismic resilience.
W.A. Rasic Construction expressed pride in contributing its expertise to the landmark project, emphasizing the team's commitment to completing the complex scope with the highest safety, precision, and innovation standards.
Designed to meet the evolving needs of a growing population and the increasing severity of climate-driven storm events, the new outfall tunnel will provide redundancy for the region's aging 1937 and 1958-era tunnels. It also marks the first use of a post-tensioned concrete segmental lining system in North America—an advanced engineering approach previously used only a few times globally.
Tunneling will be executed with a single-pass Tunnel Boring Machine (TBM), navigating soft ground and hard rock conditions, including sections passing through the Palos Verdes Fault Zone. The alignment's varying depth and ground pressures—ranging from 1 to 9 bar—make it one of the most technically demanding tunneling operations in North America.
The tunnel project is a critical component of Southern California's long-term infrastructure resilience strategy. The project directly supports the region's climate adaptation goals and environmental stewardship mandates by improving outfall capacity and seismic durability.
W.A. Rasic Construction's expertise in large-diameter pipeline installation and deep excavation makes the firm uniquely suited to handle the technical complexities of this assignment. The company's work will also generate skilled trade jobs throughout the Los Angeles area, contributing to local economic growth while reinforcing the West Coast's leadership in forward-looking utility infrastructure.
About W.A. Rasic Construction
W.A. Rasic Construction Company, founded in 1978 by Walter A. Rasic, Sr., is a leading utility contractor specializing in underground construction, water, wastewater, power, communication, gas & oil, and heavy civil infrastructure. With over 45 years of experience, W.A. Rasic Construction is trusted by both public agencies and private sector clients across the Western United States for its commitment to quality and long-term partnerships, building a reputation for quality, safety, and reliability.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Joby Aviation (JOBY) Reaches Milestone in FAA Certification with First Conforming Aircraft
Joby Aviation recently announced its preparation for the final assembly of its first conforming aircraft for the Type Inspection Authorization (TIA) flight tests, a crucial milestone aligning with FAA standards. This development underscores the company's significant progress towards commercialization and may have contributed to the impressive 185% share price increase over the last quarter. The market's general upward trend during this period would have supported such a remarkable rise. Joby's advances in product development, strategic alliances, and facility expansion likely added weight to its price movement as investors remain optimistic about its future. We've identified 5 possible red flags with Joby Aviation (at least 1 which is a bit concerning) and understanding the impact should be part of your investment process. AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. Over the past year, Joby Aviation's shares experienced an impressive total return of 285.54%. This exceptional performance stands in stark contrast to the US market's 22.4% return over the same period and the US Airlines industry's 82.1% return, highlighting Joby's substantial gain relative to its peers and the broader market. The developments mentioned in the introduction, particularly Joby's advancements in conforming aircraft assembly and strategic partnerships, could significantly influence revenue and earnings forecasts. Despite a current revenue of just US$111,000 and being forecast to remain unprofitable over the next three years, these milestones may lay the groundwork for future growth. However, the high share price, presently at US$18.93, has surpassed analysts' consensus price target of US$8.75, indicating a significant premium compared to expectations. This disparity suggests heightened market optimism, which investors should consider when evaluating Joby's long-term prospects. Our expertly prepared valuation report Joby Aviation implies its share price may be too high. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include JOBY. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data
Business Wire
21 minutes ago
- Business Wire
Getlink SE: Shuttle Traffic in July 2025
PARIS--(BUSINESS WIRE)--Regulatory News: Getlink SE (Paris:GET): In July 2025, LeShuttle Freight carried 100,401 trucks, down 2% compared to July 2024. Since 1 January, close to 700,000 trucks have crossed the Channel on board the Shuttles. LeShuttle carried 267,359 passenger vehicles in July, up 4% compared to July 2024. More than 1,250,000 passenger vehicles have been transported since 1 January. The August traffic figures will be published on Monday 8 September 2025 before the market opens. About Getlink Getlink SE (Euronext Paris: GET), through its subsidiary Eurotunnel, is the concession holder until 2086 for the Channel Tunnel infrastructure and operates Truck Shuttles and Passenger Shuttles (cars and coaches) between Folkestone (UK) and Calais (France). Since 31 December 2020 Eurotunnel has been developing the smart border to ensure that the Tunnel remains the fastest, most reliable, easiest and most environmentally friendly way to cross the Channel. Since it opened in 1994, more than 518 million people and more than 106 million vehicles have travelled through the Channel Tunnel. This unique land link, which carries a quarter of trade between the Continent and the United Kingdom, has become a vital link, reinforced by the ElecLink electricity interconnector installed in the Tunnel, which helps to balance energy needs between France and the United Kingdom. Getlink completes its sustainable mobility services with its rail freight subsidiary Europorte. Committed to "low-carbon" services that control their impact on the environment, Getlink has made the place of people, nature and territories a central concern.
Business Wire
21 minutes ago
- Business Wire
ViruSure launches pioneering first-in-class viral contamination test for biopharmaceuticals using Oxford Nanopore technology
OXFORD, England & VIENNA, Austria--(BUSINESS WIRE)--ViruSure, a global leader in pathogen safety testing for biopharmaceuticals, and Oxford Nanopore Technologies ('Oxford Nanopore') (LSE: ONT), the company behind a new generation of molecular sensing technology based on nanopores, today announce the launch of the industry's first Good Laboratory Practice (GLP) validated adventitious viral agent (AVA) detection test using nanopore-based sequencing technology. The ViruSure test has been developed and evaluated under rigorous conditions and is powered by Oxford Nanopore's advanced molecular sensing platform. It will be used for the detection of viral contamination within the manufacturing process, providing biopharmaceutical teams with richer viral detection insights and faster time-to-result, accessibly and affordably. A rapid and sensitive test, it can detect AVAs regardless of virus type, to improve confidence in biomanufacturing safety. Viral contamination remains one of the most significant threats to biopharmaceutical manufacturing, causing production delays and potential biologic, vaccine and cell and gene therapy product shortages. Traditional viral detection methods can take months to provide the full panel of results, with each individual test often taking more than 14 days, and contaminants still going undetected or reported as false positives. This innovation addresses a critical need to streamline AVA detection within biomanufacturing, a rapidly growing market currently valued at $20 billion, of which at least $4 billion is related to AVA testing. Global regulatory authorities have also recognised the urgent industry demand for faster and more reliable solutions and actively encouraged the adoption of advanced sequencing-based testing methods. i Dr Andy Bailey, CEO of ViruSure, commented: 'The development of this cutting-edge test for adventitious agents marks a major advancement in the industry's ability to detect a wide range of contaminants with exceptional sensitivity. Offering significantly improved specificity compared to traditional short-read next-generation sequencing methods, this innovation sets a new benchmark in virus detection. Powered by Oxford Nanopore technology, the test produces datasets with minimal background noise, greatly simplifying the identification of potential viral signals. This crucial feature supports biopharmaceutical manufacturers in achieving faster product evaluation and release, enhancing both safety and efficiency.' Gordon Sanghera, CEO Oxford Nanopore, commented: 'Contamination during the biomanufacturing process can pose considerable risks to patient safety, as well as production delays and drug shortages, which is not wanted by biopharmaceutical companies – nor the patients and health systems they serve. With the introduction of this first-in-class test, ViruSure is directly addressing the industry's critical demand for rapid, information-rich, and cost-effective viral detection methods, and we're proud to have played a key role in its development.' ViruSure and Oxford Nanopore are also working together to introduce a Good Manufacturing Process (GMP)-validated solution, which they expect will follow shortly. About ViruSure ViruSure, an Asahi Kasei Life Science company, is a leading global Contract Research Organization specializing in virus and prion biosafety testing for the biopharmaceutical and life science industries, with more than 20 years of experience. Located in Vienna, Austria, ViruSure partners with industry to support their quality control testing needs and ensure the safety and purity of biopharmaceuticals, cell & gene therapies, and vaccines. ViruSure is an integral part of the Biosafety Testing Services Unit of Asahi Kasei Life Sciences. To learn more about ViruSure, visit About Oxford Nanopore Technologies Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for faster, information rich, accessible and affordable molecular analysis. The first application is DNA/RNA sequencing, and the technology is in development for the analysis of other types of molecules including proteins. The technology is used in more than 125 countries to understand and characterise the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses, and whole environments. Oxford Nanopore Technologies products are intended for molecular biology applications and are not intended for diagnostic purposes. For more, visit:
